论文部分内容阅读
目的:通过观察疏肝祛瘀方治疗早中期膝骨关节炎的疗效,探讨疏肝祛瘀方治疗早中期膝骨关节炎的临床疗效。方法:将符合纳入标准的早中期膝骨关节炎患者60例,随机分为对照组与治疗组,每组30例,治疗组予疏肝祛瘀方药内服4周,对照组予双醋瑞因胶囊口服4周,然后观察其临床疗效及膝关节液IL-1β、血清载脂蛋白A-1的含量。结果:两组治疗前后按视觉模拟评分法评分及西安大略麦马斯特大学骨关节炎指数评分、膝关节肿胀评分、膝关节液IL-1β的含量的比较,均有显著降低,而两组间治疗前后比较无明显差异。血清载脂蛋白A-1的含量在各组治疗前后及两组间比较,差异均无统计学意义。结论:疏肝祛瘀方治疗早中期膝骨关节炎能取得与双醋瑞因治疗膝骨关节炎同样的临床疗效,两者均能降低膝关节液IL-1β的含量,血清载脂蛋白A-1作为判断膝骨关节炎的临床诊治指标均不敏感。
Objective: To observe the curative effect of Shugan Quyu Decoction on early and mid-term knee osteoarthritis and to explore the clinical effect of Shugan Quyu prescription on early and mid-term knee osteoarthritis. Methods: Sixty patients with knee osteoarthritis who met the inclusion criteria were randomly divided into control group and treatment group, with 30 cases in each group. The treatment group was given Shugan Quyu Decoction for 4 weeks. The control group was treated with diacerein The capsules were orally administered for 4 weeks, and then the clinical efficacy and the contents of IL-1β in knee joint fluid and serum apolipoprotein A-1 were observed. Results: Before and after treatment, the score of visual analogue scale and the score of osteoarthritis index, knee swelling score and the content of IL-1β in knee joint fluid of the two groups were significantly decreased in both groups Between before and after treatment no significant difference. Serum apolipoprotein A-1 levels in each group before and after treatment and between the two groups, the difference was not statistically significant. Conclusion: Shuganquyu Decoction can treat knee osteoarthritis in the early and middle stages with the same clinical efficacy as diacerein in the treatment of knee osteoarthritis, both of which can reduce the content of IL-1β in knee joint fluid and serum apolipoprotein A -1 as a clinical diagnosis of knee osteoarthritis indicators are not sensitive.